Compare D Wave Quantum Inc (QBTS) vs Royalty Pharma plc Class A Ordinary Shares (RPRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
D Wave Quantum Inc vs Royalty Pharma plc Class A Ordinary Shares — how do they compare? D Wave Quantum Inc trades at $14.51 (market cap $5.54B), while Royalty Pharma plc Class A Ordinary Shares trades at $57 (market cap $25.27B). The key difference: Royalty Pharma plc Class A Ordinary Shares is far larger — about 4.6× D Wave Quantum Inc's market cap, and Royalty Pharma plc Class A Ordinary Shares pays a 1.66% dividend while D Wave Quantum Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold D Wave Quantum Inc for 32 Days and Royalty Pharma plc Class A Ordinary Shares for 0 Days on average.
| QBTS | RPRX | |
|---|---|---|
Market Cap | $5.54B | $25.27B |
Volume | 16,671,452 | 3,671,183 |
Sector | Technology | Health |
52-Week High | $44.78 | $63.96 |
52-Week Low | $12.98 | $35.44 |
Typical Hold Time | 32 Days | 0 Days |
Enterprise Value | $5.04B | $32.50B |
Dividend Yield | — | 1.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
D-Wave Quantum (QBTS) trades at $14.42, down 5.26% today, amid bearish technical signals and ongoing legal investigations. The company shows severe financial stress with a -2,001.59% net income margin and -$355M net loss in 2025, though it maintains a 64.19% gross margin. Revenue declined from $25M to $12M year-over-year, while cash flow turned negative in 2026. Despite 100% analyst buy ratings with a $34.38 consensus target, multiple law firms are investigating potential securities law violations.
The stock faces significant fundamental challenges with massive losses and declining revenue, offset by strong analyst optimism about quantum computing potential. Key risks include ongoing legal probes, cash burn acceleration, and competitive pressures in the emerging quantum sector. The current price sits 58% below analyst targets, creating potential upside if execution improves, but substantial operational turnaround is needed.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About D Wave Quantum Inc
D-Wave Quantum Inc. is a global leader in the development and delivery of quantum computing systems, software, and services. The company specializes in annealing quantum computers designed to solve complex optimization problems across industries such as logistics, materials science, and financial modeling. D-Wave offers its technology through the cloud, allowing customers to build and run real-world quantum applications today, making it a key player in the commercialization of quantum computing.
Read more on QBTS →About Royalty Pharma plc Class A Ordinary Shares
Royalty Pharma acquires interests in royalties from biopharmaceutical products. Its model gives it exposure to medicines developed and sold by other life sciences companies.
Read more on RPRX →
